Raymond James & Associates’s GoodRx Holdings GDRX Stock Holding History

Raymond James & Associates’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$2.73M	Buy	394,006 +267,951	+213%	+$2.1M	﹤0.01%	2033
2024 Q2	$983K	Buy	126,055 +21,645	+21%	+$160K	﹤0.01%	2631
2024 Q1	$741K	Buy	104,410 +75,810	+265%	+$501K	﹤0.01%	2799
2023 Q4	$192K	Buy	+28,600	New	+$161K	﹤0.01%	3531
2022 Q4	–	Sell	-12,089	Closed	-$56K	–	3973
2022 Q3	$56K	Sell	12,089 -2,252	-16%	-$14.2K	﹤0.01%	3693
2022 Q2	$85K	Buy	14,341 +535	+4%	+$5.96K	﹤0.01%	3708
2022 Q1	$267K	Buy	13,806 +2,675	+24%	+$61.3K	﹤0.01%	3486
2021 Q4	$364K	Sell	11,131 -35,930	-76%	-$1.45M	﹤0.01%	3325
2021 Q3	$1.93M	Sell	47,061 -21,250	-31%	-$771K	﹤0.01%	2132
2021 Q2	$2.46M	Sell	68,311 -2,681	-4%	-$98.9K	﹤0.01%	1959
2021 Q1	$2.77M	Buy	70,992 +3,902	+6%	+$175K	﹤0.01%	1803
2020 Q4	$2.71M	Buy	+67,090	New	+$3.08M	﹤0.01%	1710

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

LCM

Lakewood Capital Management New York $1.58B AUM 0.92% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James & Associates's GDRX Position: Q3 2024 in Review

Raymond James & Associates increased its GoodRx Holdings (GDRX) stake by 213% in Q3 2024, buying an estimated $2.1M and bringing the position to 394,006 shares worth $2.73M. The position accounts for ﹤0.01% of the portfolio, ranked #2033.

Raymond James & Associates first reported a position in GDRX in Q4 2020 and has held it in 12 quarters since. The position peaked at $2.77M in Q1 2021. 168 funds tracked by Wall St. Rank hold GDRX as of Q3 2024.

Raymond James & Associates held 394,006 shares of GoodRx Holdings worth $2.73M as of Q3 2024.
Raymond James & Associates bought 267,951 GoodRx Holdings shares in Q3 2024, an estimated $2.1M.
GoodRx Holdings made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2033 holding.
Raymond James & Associates first reported a position in GoodRx Holdings in Q4 2020 and has held it in 12 quarters since.
Raymond James & Associates's GoodRx Holdings position peaked at $2.77M in Q1 2021.
168 funds tracked by Wall St. Rank held GoodRx Holdings as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.